BOUCHERVILLE, Québec, Oct. 18, 2023 (GLOBE NEWSWIRE) -- LSL Pharma Group Inc. (TSXV: LSL), (the œCompany or œLSL Pharma Group), a Canadian integrated pharmaceutical company, announced today...
NEW YORK--(BUSINESS WIRE)--Fera is pleased to announce that FDA has granted Orphan Drug Designation for Phospholine Iodide (echothiophate iodide for ophthalmic solution) as a treatment for Stargardt disease.
Decades-old glaucoma drug tossed aside by Pfizer gets a new life
Nicox and Fera Pharmaceuticals announced that Fera will evaluate naproxcinod as a potential adjuvant treatment for patients with COVID-19 infection. Subject to successful completion of the ongoing manufacturing of naproxcinod test material, Fera plans to initiate preclinical proof-of-concept studies in models of COVID-19 infection in early 2021.
NEW YORK--(BUSINESS WIRE)--Fera is pleased to announce that, in addition to its already marketed 100-count bottle package size, it has now launched a 100-count unit dose blister package as well. The advantages of unit dose packaging include improved safety for hospital staff and patients and to help minimize inaccurate dosing.
FERA PHARMS Generic Levothyroxine Sodium Receives FDA Approval